Suchen und Finden

Titel

Autor

Inhaltsverzeichnis

Nur ebooks mit Firmenlizenz anzeigen:

 

Next Generation Kinase Inhibitors - Moving Beyond the ATP Binding/Catalytic Sites

Next Generation Kinase Inhibitors - Moving Beyond the ATP Binding/Catalytic Sites

von: Paul Shapiro

Springer-Verlag, 2020

ISBN: 9783030482831 , 217 Seiten

Format: PDF

Kopierschutz: DRM

Windows PC,Mac OSX Apple iPad, Android Tablet PC's

Preis: 128,39 EUR

Exemplaranzahl:


Mehr zum Inhalt

Next Generation Kinase Inhibitors - Moving Beyond the ATP Binding/Catalytic Sites


 

Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this way, protein kinases help monitor the extracellular environment and integrate signaling cues that, for the most part, are beneficial for human health and survival. However, protein kinases are often dysregulated and responsible for the initiation and progression of many types of cancers, inflammatory disorders, and other diseases. Thus, decades of research have revealed much about how protein kinases are regulated and approaches to inhibit these enzymes to treat disease. However, nearly 30 years since the identification of the first clinically beneficial small molecule protein kinase inhibitor, there are only a few examples where these drugs provide sustained and durable patient responses. The goal of this book is to provide biomedical scientists, graduate, and professional degree students insight into different approaches using small molecules to block specific protein kinase functions that promote disease. 

Paul Shapiro has a long-standing interest in protein kinases and their role in regulating cellular functions during disease. Specific areas focus on the discovery and development of function-selective mitogen-activated protein (MAP) kinase inhibitors with the goal of mitigating cancer cell proliferation and inflammation-induced lung injury associated with respiratory diseases. He received a Bachelor of Science degree from the University of Wisconsin-Madison and his doctorate in molecular physiology and biophysics from the University of Vermont. Dr. Shapiro completed post-doctoral training in the Department of Chemistry and Biochemistry at the University of Colorado-Boulder and is currently a professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy.